Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;183(1):71-77.
doi: 10.1111/bjd.19163. Epub 2020 Jun 10.

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

C Galván Casas  1 , A Català  2 , G Carretero Hernández  3 , P Rodríguez-Jiménez  4 , D Fernández-Nieto  5 , A Rodríguez-Villa Lario  6 , I Navarro Fernández  7 , R Ruiz-Villaverde  8 , D Falkenhain-López  9 , M Llamas Velasco  4 , J García-Gavín  10 , O Baniandrés  11 , C González-Cruz  12 , V Morillas-Lahuerta  13 , X Cubiró  14 , I Figueras Nart  15 , G Selda-Enriquez  5 , J Romaní  16 , X Fustà-Novell  17 , A Melian-Olivera  5 , M Roncero Riesco  18 , P Burgos-Blasco  5 , J Sola Ortigosa  19 , M Feito Rodriguez  20 , I García-Doval  21
Affiliations

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

C Galván Casas et al. Br J Dermatol. 2020 Jul.

Abstract

Background: The cutaneous manifestations of COVID-19 disease are poorly characterized.

Objectives: To describe the cutaneous manifestations of COVID-19 disease and to relate them to other clinical findings.

Methods: We carried out a nationwide case collection survey of images and clinical data. Using a consensus we described five clinical patterns. We later described the association of these patterns with patient demographics, the timing in relation to symptoms of the disease, the severity and the prognosis.

Results: The lesions may be classified as acral areas of erythema with vesicles or pustules (pseudo-chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%) and livedo or necrosis (6%). Vesicular eruptions appear early in the course of the disease (15% before other symptoms). The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-19 disease (59% after other symptoms), while the rest tend to appear with other symptoms of COVID-19. The severity of COVID-19 shows a gradient from less severe disease in acral lesions to more severe in the latter groups. The results are similar for confirmed and suspected cases, in terms of both clinical and epidemiological findings. Alternative diagnoses are discussed but seem unlikely for the most specific patterns (pseudo-chilblain and vesicular).

Conclusions: We provide a description of the cutaneous manifestations associated with COVID-19 infection. These may help clinicians approach patients with the disease and recognize cases presenting with few symptoms. What is already known about this topic? Previous descriptions of cutaneous manifestations of COVID-19 were case reports and mostly lacked illustrations. What does this study add? We describe a large, representative sample of patients with unexplained skin manifestations and a diagnosis of COVID-19, using a consensus method to define morphological patterns associated with COVID-19. We describe five clinical patterns associated with different patient demographics, timing and prognosis, and provide illustrations of these patterns to allow for easy recognition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
All of the patients shown had confirmed COVID‐19. (a, b) Acral areas of erythema–oedema with vesicles or pustules (pseudo‐chilblain). (c) Monomorphic (i.e. at same stages) disseminated vesicles. (d) Urticarial lesions.
Figure 2
Figure 2
All of the patients shown had confirmed COVID‐19. (a) Maculopapular eruption. Some of the lesions are perifollicular. (b) Acral infiltrated papules (pseudovesicular). (c) Acral papules (erythema multiforme like). (d) Livedoid areas.
See this image and copyright information in PMC

Comment in

References

    1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA 2020; DOI: 10.1001/jama.2020.1097. - PubMed
    1. Li Q, Guan X, Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus‐infected pneumonia. N Engl J Med 2020; 382:1199–207. - PMC - PubMed
    1. Recalcati S. Cutaneous manifestations in COVID‐19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34:e212–13. - PubMed
    1. Joob B, Wiwanitkit V. COVID‐19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82:e177. - PMC - PubMed
    1. Mazzota F, Troccoli T. Acute acro‐ischemia in the child at the time of COVID‐19. Available at: https://www.fip-ifp.org/wp-content/uploads/2020/04/acroischemia-ENG.pdf (last accessed 4 May 2020).

MeSH terms